ROCKVILLE, Md., Dec. 30, 2022 (GLOBE NEWSWIRE) -- OncoC4, Inc., a clinical-stage biopharma company developing novel immunotherapies for cancer, today announced that the first patient has been dosed in the Phase 2 combination study of ONC-392, a nextgen target-preserving anti-CTLA-4 antibody and KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in patients with platinum-resistant ovarian cancer (PROC) (PRESERVE-004, NCT5446298).
The patient was dosed at the Women's Cancer Care Associates, LLC, located in Albany New York. Dr. Joyce Barlin is the site Principal Investigator (PI). The study is sponsored by OncoC4, Inc., in collaboration with Merck (known as MSD outside the US and Canada) and the GOG Foundation Inc.
“It is an exciting time for immunotherapy clinical trial research. I am incredibly grateful for the opportunity to serve as the Co-PI on this Phase 2 trial with Dr. Bradley Monk. We are thrilled to dose the first patient at our institution with this innovative immunotherapy combination, which hopes to address the unmet need in platinum-resistant ovarian cancer,” said Dr. Joyce Barlin.
Read the entire press release here.
Source: OncoC4 Announces First Patient Dosed in PRESERVE-004
